Protection of mice against Brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides.
Brucella abortus, a gram negative, facultative intracellular pathogen causes brucellosis in many animal species and humans. Although live, attenuated vaccines are available against this infection, they suffer from certain limitations. Therefore, the development of an effective subunit vaccine against brucellosis is an area of intense research. The outer membrane proteins (OMPs) of Brucella species have been extensively studied for its immunogenicity and protective ability. We have investigated the potential of CpG ODN to enhance the immunogenicity and protective efficacy of recombinant 28 kDa outer membrane protein (rOMP28) of Brucella melitensis. The study demonstrated vigorous immunoglobulin G (IgG) response of OMP28. The administration of rOMP28 with CpG caused increased cell mediated immune response in terms of induced IgG2a, T-cell proliferation and up-regulation of type I cytokine expression. In contrast, the free antigen suppressed the interferon gamma (type I cytokine) production on in-vitro stimulation of spleenocytes. The result indicates the role of OMP28 in the down regulation of IFN-gamma production. Moreover, the B. abortus S-19 vaccinated mice showed highest production of IL-4 and IFN-gamma. The protective ability of the antigen was evaluated by systemic bacterial clearance after challenging the mouse with B. abortus 544 pathogen. The level of protection was significant in rOMP28+CpG treated mice but was lower than the required level. The results of the present study indicate that rOMP28 could be an immunogen capable of inducing both humoral and cellular immune response. The humoral response was biased towards Th1 type when it was co-administered with CpG.
Kaushik
Purushottam
P
Division of Veterinary Public Health, Bihar Veterinary College, Patna, Bihar, India. drkaushikvet@rediffmail.com
Singh
Dhirendra K
DK
Kumar
S Vinoth
SV
Tiwari
Ashok K
AK
Shukla
Gunjan
G
Dayal
Shanker
S
Chaudhuri
Pallav
P
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001428:Bacterial Vaccines / Q000276:immunology* / Q000494:pharmacology; D015153:Blotting, Western; D002003:Brucella abortus / Q000276:immunology*; D002007:Brucellosis, Bovine / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control*; D002417:Cattle; D004247:DNA / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007114:Immunization; D007074:Immunoglobulin G / Q000097:blood; D007132:Immunoglobulin Isotypes / Q000097:blood; D007371:Interferon-gamma / Q000378:metabolism; D015847:Interleukin-4 / Q000032:analysis; D016014:Linear Models; D008565:Membrane Proteins / Q000235:genetics / Q000276:immunology*; D051379:Mice; D009838:Oligodeoxyribonucleotides; D011817:Rabbits; D014614:Vaccines, Synthetic / Q000276:immunology / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; C106040:BP26 protein, Brucella; D001428:Bacterial Vaccines; C423449:CpG ODN 1826; D007074:Immunoglobulin G; D007132:Immunoglobulin Isotypes; D008565:Membrane Proteins; D009838:Oligodeoxyribonucleotides; D014614:Vaccines, Synthetic; D015847:Interleukin-4; D007371:Interferon-gamma; D004247:DNA